Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam. 2011

Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
Agenzia Sanitaria e Sociale Regionale Emilia-Romagna, Bologna, Italy.

This study aimed to evaluate the accuracy of routine systems (Vitek2 cards AST-N022 and AST-N026; Kirby Bauer; Etest) for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam. Vitek2 (card AST-N022) showed the worst performance; the other three methods (Vitek2 card AST-N026, Kirby-Bauer and E-test) performed comparably but never fulfilled the minimal standard proposed by FDA.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010397 Penicillanic Acid A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed) Acid, Penicillanic
D010878 Piperacillin Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics. AB-Piperacillin,Cl-227193,Pipcil,Pipera-Hameln,Piperacillin Curasan,Piperacillin Fresenius,Piperacillin Hexal,Piperacillin Monosodium Salt,Piperacillin Sodium,Piperacillin-Ratiopharm,Pipercillin,Pipracil,Pipril,T-1220,T1220,AB Piperacillin,Cl 227193,Cl227193,Curasan, Piperacillin,Monosodium Salt, Piperacillin,Pipera Hameln,Piperacillin Ratiopharm,Salt, Piperacillin Monosodium,Sodium, Piperacillin,T 1220
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077725 Piperacillin, Tazobactam Drug Combination An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS. Piperacillin - Tazobactam,Piperacillin-Tazobactam Combination Product,Pipercillin Sodium - Tazobactam Sodium,Pipercillin Sodium, Tazobactam Sodium Drug Combination,Tazocel,Tazocillin,Tazocin,Zosyn,Piperacillin Tazobactam,Piperacillin Tazobactam Combination Product,Pipercillin Sodium Tazobactam Sodium,Tazobactam, Piperacillin -
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001431 Bacteriological Techniques Techniques used in studying bacteria. Bacteriologic Technic,Bacteriologic Technics,Bacteriologic Techniques,Bacteriological Technique,Technic, Bacteriological,Technics, Bacteriological,Technique, Bacteriological,Techniques, Bacteriological,Bacteriologic Technique,Bacteriological Technic,Bacteriological Technics,Technic, Bacteriologic,Technics, Bacteriologic,Technique, Bacteriologic,Techniques, Bacteriologic

Related Publications

Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
April 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
April 1999, Journal of chemotherapy (Florence, Italy),
Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
March 2008, The Journal of antimicrobial chemotherapy,
Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
November 2017, The Journal of antimicrobial chemotherapy,
Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
July 2003, Journal of clinical microbiology,
Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
January 1997, Chemotherapy,
Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
January 2020, Journal of clinical microbiology,
Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
January 2017, Journal of clinical microbiology,
Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
March 2002, Antimicrobial agents and chemotherapy,
Carlo Gagliotti, and Mario Sarti, and Carla Sabia, and Raffaele Gargiulo, and Gian Maria Rossolini, and Carmelina Carillo, and Carla Cassani, and Antonio Paolo Cipolloni, and Federica Pedna, and Maria Rita Rossi, and Silvia Storchi Incerti, and Giovanna Testa, and Claudia Venturelli, and Maria Luisa Moro
September 2004, Journal of medical microbiology,
Copied contents to your clipboard!